Immunitas Therapeutics to Present First-in-Human Data for Novel Anti-CD161 Antibody IMT-009 at AACR 2026
核心洞察
Immunitas Therapeutics (搜索) will present clinical data from its Phase 1/2a trial of IMT-009, a first-in-class anti-CD161 antibody, at the AACR Annual Meeting in April 2026.
The presentation will include data supporting both monotherapy and combination treatment potential for solid tumors (搜索) and hematologic malignancies (搜索).
IMT-009 is a fully human monoclonal antibody that blocks CD161 interaction with its ligand CLEC2D (搜索), with preclinical data showing enhanced anti-tumor activity.
Immunitas Therapeutics (搜索) announced it will present clinical data from its Phase 1/2a trial of IMT-009, a first-in-class anti-CD161 antibody, at the American Association for Cancer (搜索) Research (AACR) Annual Meeting scheduled for April 17-22, 2026 in San Diego, California. The data presentation supports continued development of IMT-009 as a novel cancer immunotherapy for treatment of solid tumors (搜索) and hematologic malignancies (搜索).
Clinical Trial Design and Presentation Details
The presentation, titled "A first-in-human, dose escalation (DE) and biomarker cohort expansion (BCE) of IMT-009 (IMT) in advanced cancer (搜索) and Phase 1b (Ph1b) combination with fruquintinib (F) in microsatellite stable colorectal cancer (搜索) (MSS CRC)," will be delivered by Dr. Susanna V. Ulahannan from The University of Oklahoma, Stephenson Cancer Center/SCRI. The poster session is scheduled for Monday, April 20, 2026, from 9:00 a.m. to 12:00 p.m. PT in Poster Section 50.
The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as both monotherapy and combination treatment. A key objective includes identifying the Recommended Phase 2 Dose (RP2D) for future clinical development.
Mechanism of Action and Preclinical Evidence
IMT-009 is a fully human, Fc-attenuated IgG1 monoclonal antibody that binds to CD161 and blocks its interaction with its ligand, CLEC2D (搜索). Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity, providing the scientific rationale for its clinical development.
The antibody is currently under evaluation in a Phase 1/2a clinical trial for use as both monotherapy and combination treatment for solid tumor and hematological malignancies.
Company Background and Development Pipeline
Immunitas Therapeutics (搜索) is a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for patients with autoimmune diseases (搜索) and cancer (搜索). The company's specialized knowledge of the CD161 pathway has yielded multiple differentiated antibody therapeutics, including IMT-009 for cancer treatment and IMT-380 for autoimmune conditions.
Founded in 2019 by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT, Immunitas has raised over $120 million from investors including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund.